4594.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:15):

Stats
Today's Volume	498 600
Average Volume	857 137
Market Cap	3.96B
EPS	¥0 ( 2024-02-09 )
Next earnings date	( ¥0 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-2.93
ATR14	¥0.327 (0.57%)

Volume Correlation

Long: 0.01 (neutral)

Short: -0.32 (neutral)

Signal:(51.241) Neutral

BrightPath Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BrightPath Correlation - Currency/Commodity

-0.01
( neutral )

0.03
( neutral )

0.00
( neutral )

0.06
( neutral )

0.19
( neutral )

-0.05
( neutral )

BrightPath Financials

Annual	2022
Revenue:	¥5.28M
Gross Profit:	¥3.39M (64.11 %)
EPS:	¥-24.90

Q3	2023
Revenue:	¥23 000.00
Gross Profit:	¥18 000.00 (78.26 %)
EPS:	¥-6.32

Q2	2023
Revenue:	¥28 000.00
Gross Profit:	¥21 000.00 (75.00 %)
EPS:	¥-4.10

Q1	2023
Revenue:	¥16 000.00
Gross Profit:	¥12 000.00 (75.00 %)
EPS:	¥-4.70

Financial Reports:

No articles found.

BrightPath

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.